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SUMMARY 
Eight patients with DSM-III-defined panic attacks were compared to four normal subjects on hormonal 
and physiological variables measured at six predetermined times through 24 hr and also during nine 
"spontaneous" attacks. Levels at predelermined times were not different, other than a reduction of urinary 
unconjugated epinephrine in patients. Plasma prolactin was elevated at the peak of most of  the attacks 
and correlated with attack severity. Plasma cortisol and growth hormone, and heart rate, were elevated 
during some attacks, and plasma norepinephrine showed small increases. Significant plasma epinephrine 
and MHPG changes were not observed. 
INTRODUCTION 
HORMONAL CHANGES are associated with stress in normal subjects (Rose, 1980) and in people 
with mixed depression/anxiety (Wyatt et al. ,  1971) and primary anxiety disorders including 
phobias (Chosy et al.,  1970; Nesse et al.,  1985a), generalized anxiety (Mathew et al.,  1982; 
Rosenbaum et al. ,  1983) and panic anxiety. Studies in panic have included resting conditions 
(Nesse et al.,  1984), normal activity (Hamlin et al. ,  1983; Ballenger et al. ,  1984; Nesse et al.,  
1985b) and pharmacologically (Appleby et al.,  1981; Charney et al.,  1984, 1985; Liebowitz 
et al.,  1985, 1986; Carr et al.,  1986) and situationally induced (Ko et al. ,  1983) panic attacks. 
Challenge tests in panic patients which did not produce panic attacks have also been studied 
(Grunhaus et al. ,  1983; Nesse et al.,  1984; Charney and Heninger, 1986; Roy-Byrne et al.,  
1986a,b). However, despite the presence of at least some spontaneous panic attacks as a sine 
qua non for the DSM-III-defined diagnosis of panic disorder (American Psychiatric Association, 
1980), no studies of endocrine changes associated with spontaneous panic attacks have been 
reported. Therefore, hormonal as well as physiological changes were monitored during nine 
spontaneous attacks in patients with this disorder, and the same variables were also studied in 
panic patients and normal subjects at six predetermined times over 24 hr. 
MATERIALS AND METHODS 
Subjects 
Eight patients with DSM-Ill-defined panic attacks (six women, mean age = 33 years) and four normal subjects (two 
women, mean age = 29 years) were studied. The mean duration of illness was 6.6 years (range: 1.5 - 19 years), and 
the self-reported mean duration of panic attacks was 35 min (range 1 min to 1 hr). Four patients reached criteria for 
a diagnosis of agoraphobia; five had other phobias as well, including heights, elevators, flying, driving and being alone. 
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All patients reported an average occurrence of at least one panic attack per day for the previous several weeks. 
All subjects were screened with a psychiatric evaluation, medical history, physical examination and laboratory studies 
including complete blood count, blood chemistries, thyroid function tests and electrocardiograms; all were normal, 
other than the panic diagnosis in patients. All subjects were on a normal daytime waking-night-time sleep cycle, and 
there were no differences between patients and normals in average daily exercise level. This research was approved 
by the University of Michigan Institutional Review Board for Human Use in Research, and all subjects gave informed 
consent. 
Procedure 
Subsequent to the evaluation, patients on any medication were gradually withdrawn; all subjects were drug-free for 
at least 1 week prior to study. Subjects followed a low monoamine diet (Maas, 1983) and avoided caffeinated beverages 
for 3 days prior to and during the study. Subjects stayed at bedrest throughout the study period, with an indwelling 
venous catheter for sampling of blood ("heparin lock' '). Subjects were studied for approximately 36 hr in the University 
of Michigan Clinical Research Center. 
All urine, collected in 6-hr aliquots (0100-0700 hr, 0700-1300 hr, 1300-1900 hr and 1900-0100 hr), was acidified 
and refrigerated during collection, and frozen immediately after completion of collection. Blood specimens were collected 
under two different circumstances. First, blood was drawn at 4-hr intervals (0300 hr, 0700 hr, 1100 hr, 1500 hr, 1900 hr 
and 2300 hr) for 24 hr. Second, blood was drawn at four times in association with each panic attack --  at the peak 
and end of each attack, and 10 and 60 min after the end of each attack. The occurrence of a panic attack, including 
the peak and end of each attack, was defined subjectively by each patient. Patients were instructed to report an attack 
whenever they experienced the onset of any of those symptoms which were identified during the diagnostic evaluation 
as associated with DSM-III-defined panic attacks, as long as the attack also involved a feeling of fear. Subjects were 
allowed to identify "limited symptom attacks" (i,e. less than four symptoms) as well as "full" panic attacks, but to 
consider number and intensity of symptoms as well as duration in the severity ratings. 
Urine and blood specimens not associated with attacks were obtained from both patients and normal subjects. For 
blood specimens, tubes were spun in a refrigerated centrifuge and plasma was separated and frozen until assay. Blood 
pressure, pulse and oral temperature were also determined at the time of each blood draw. Rating scales, composed 
of 100-mm lines, were rated at the time of each blood draw; ratings were done for "sad, blue, depressed", "confused", 
"worried, anxious, nervous", "tense, irritable", "tired, low energy", "feeling good" and "panic severity". Also, 
at the end of each attack, overall attack severity was rated 0 -10  (none = 0, most ever = 10). Finally, all subjects 
wore Holter monitors (recorders of each heart beat) throughout the study period. 
Urine was assayed for unconjugated epinephrine and norepinephrine. Blood for plasma epinephrine and norepinephrine 
was collected into tubes containing reduced ghitathione and EGTA. Catecholamines were assayed with a radioenzymatic 
technique. Blood for the other plasma hormones (cortisol, human growth hormone and prolactin) and MHPG 
(3-methoxy-4-hydroxy-phenethyleneglycol, a metabolite of central and peripheral nervous system catecholamines) was 
collected into heparinized tubes. MHPG was assayed with a liquid chromatographic method, cortisol with a competitive- 
protein binding technique, and growth hormone and prolactin with radioimmunoassays. 
RESULTS 
O f  the eight  patients studied, four  had no attacks during the study per iod,  one had one,  two 
had two each and one had four. Fo r  the nine attacks, the mean t ime o f  attack onset  was 
approximate ly  1000 hr,  and the mean  subject ive severi ty rating was 6 .22 /10  (SD -- 1.92, range 
= 4 - 9 ) .  
Hormona l  and physiological  data obtained at p rede te rmined  t imes are  presented for patients 
who  had at least one  attack (n = 4), patients who  had none (n = 4) and normal  subjects (n 
= 4) (Fig.  1). A signif icant  d i f ference  ( repeated-measures  A N O V A ,  two-tai led p = 0.02) was 
observed  be tween  these three groups  for ur inary epinephr ine;  normal  subjects were  highest  and 
patients who  did not  have  attacks were  lowest .  There  was also a t rend for d i f ferences  in ur inary 
norepinephrine (repeated-measures  A N O V A ,  two-tai led,  p = 0.06),  again with normal  subjects 
the highest. For  the six plasma hormones,  no significant differences among groups were  observed,  
and the actual levels  were  within the expected ranges for  normal  subjects (Krieger ,  1979; Maas ,  
1983; Zieg le r  and Lake,  1984; Cameron  et a l . ,  1987). 
There  was a t rend for  patients who  had attacks to have  lower  heart  rates than the other  two 
groups (repeated-measures A N O V A ,  two-tailed, p = 0.07); however ,  this was due to one patient 
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who  had an average  24-hr  heart  rate, by Hol te r  moni tor ing ,  o f  55.8 beats per  min.  Without  
this patient,  the average  Hol te r -de te rmined  rates were  72.3,  75.2 and 78.5 beats per  min for 
patients with attacks, normal  subjects and patients without  attacks, respect ively .  The re  were  
no di f ferences  among  the groups  for  the other  three physiological  variables.  Variabi l i ty  o f  these 
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FIG. 1. Hormone and physiological variables measured at predetermined times. Plasma variables--prolactin (pro) 
(ng/ml), growth hormone (GH) (ng/ml), cortisol (con) ~g/dl), 3-methyl-4-hydroxy-phenethyleneglycol (MHPG) (ng/ml), 
norepinephrine (NEp) (pg/ml) and epinephrine (Ep) (pg/ml)--and physiological variables--systolic blood pressure (SBP) 
(mm Hg), diastolic blood pressure (DBP) (mm Hg), heart rate (HR) (beats per min) and oral body temperature (T °) 
(degrees Fahrenheit) were measured at 0300 hr (3A), 0700 hr (7A), 1100 hr (11A), 1500 hr (3P), 1900 hr (7P) and 
23130 hr (liP). Urinary variables--unconjugated epinephrine (Eu) (/~g/collection) and norepinephrine (NEu) 
(#g/collection)--were measured in 6-hr aliquots [0100-0700 hr (IA-7A),  0700-1300 hr (7A- 1P), 1300-1900 hr 
(1P-7P) and 1900-0100 hr (7P- 1A)]. Measurements were made for patients who had at least one panic attack during 
the study ( • -- • ) (n = 4), patients who did not have any attacks during the study ( x .... x) (n = 4) and normal subjects 
(G--C)) (n = 4). Units of measurement are on the left-hand ordinate and measured variables are indicated in the upper 
right-hand corner of each frame. 
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TABLE I. STANDARD DEVIATIONS FOR ALL VARIABLES AT PREDETERMINED TIMES 
Code 0300 hr 0700 hr 1100 hr 1500 hr 1900 hr 2300 hr 
Plasma prolactin 1 29.5 3.4 4.7 5.0 0.81 0.97 
2 6.8 7.9 2.9 3.5 2.3 5.2 
3 5.0 26.3 3.6 2.2 17.1 1.4 
Plasma growth hormone 1 4.9 3.0 0.69 0.92 4.7 1.7 
2 2.8 55.6 6.4 1.4 4.7 3.7 
3 5.6 4.3 3.0 0.91 8.8 1.8 
Plasma cortisol 1 9.4 9.0 6.2 2.3 2.7 4.2 
2 14.9 11.5 9.9 10.4 14.9 7.4 
3 4.3 3.1 12.3 3.5 5.0 3.5 
Plasma MHPG 1 3.5 0.58 0.86 1.1 0.31 1.1 
2 0.26 0.27 0.44 1.2 0.29 1.1 
3 0.73 0.43 1.0 0.26 0.22 0.48 
Plasma norepinephrine 1 45.2 91.1 103.7 41.0 32.7 48.0 
2 53.0 77.3 26.2 84.9 22.6 73.5 
3 12.2 38.8 53.3 17.5 92.9 55.1 
Plasma epinephrine 1 4.2 5.7 14.8 12.7 17.1 17.2 
2 2.8 15.7 21.2 24.4 5.7 7.1 
3 14.1 8.5 59.4 12.0 14.8 12.0 
Systolic blood pressure 1 7.6 5.9 2.9 11.3 12.7 12.4 
2 11.9 7.2 12.2 3.2 3.1 12.9 
3 11.3 14.7 10.3 12.8 16.9 8.7 
Diastolic blood pressure 1 9.4 14.8 11.4 7.2 11.2 6.5 
2 11.0 10.0 14.8 15.5 7.4 17.7 
3 7.5 12.4 8.4 10.5 6.8 4.9 
Heart rate 1 5.7 8.6 11.3 8.0 14.0 14.2 
2 8.7 7.9 7.6 8.5 5.1 10.3 
3 7.0 3.2 5.0 7.6 9.6 5.2 
Body temperature 1 0.39 0.67 0.31 0.31 0.37 0.49 
2 0.55 1.1 0.85 0.61 0.90 0.55 
3 0.28 0.55 0.72 0.24 0.62 0.50 
0100-0700 hr 0700-1300 hr 1300-1900 hr 1900-0100 hr 
Urine norepinephrine 1 0.08 0.19 0.42 0.41 
2 0.85 0.37 0.12 0.10 
3 0.19 0.43 0.60 0.44 
Urine epinephrine 1 0.24 0.10 0.21 0.49 
2 0.40 0.21 0.19 0.51 
3 0.20 0.37 0.13 0.26 
Values are standard deviations at six predetermined times (hr) for plasma variables, and four 6-hr intervals for urinary 
variables. Codes are: 1 = patients who had attacks; 2 = patients who did not have attacks; 3 = normal subjects. 
All o f  the p lasma  h o r m o n e  and physio logica l  var iables  were  also s tudied dur ing  each o f  the 
nine panic attacks. " P r e "  and " p o s t "  basel ines were  de te rmined  by using the tempora l ly  closest  
measu remen t s  o f  the six p r ede t e rmined  t imes  be fo re  and after  each  attack. Visual  inspect ion 
o f  the aggregate  data (Fig.  2) suggests  increases  in prolact in ,  g rowth  h o r m o n e  and cort isol  at 
the peak o f  the attacks; small  increases  for  no rep inephr ine  and hear t  rate also occur red .  None  
o f  the other variables showed obvious changes at the t imes of  attack peaks and none of  the changes 
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FIG. 2. Hormone and physiological variables measured during nine "spontaneous" panic attacks in four panic patients. 
Plasma variables--prolactin (pro) (ng/ml), growth hormone (GH) (ng/ml), cortisol (tort) (tzg/dl), norepinephrine (NE) 
(pg/ml), epinephrine (E) (pg/ml) and 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) (ng/ml)--and physiological 
variables--systolic blood pressure (SBP) (ram Hg), diastolic blood pressure (DBP) (mm Hg), heart rate (HR) (beats 
per minute) and oral body temperature (T °) (degrees Fahrenheit)--were measured prior to attack ("pre"), at the peak 
and end of the attack as defined subjectively by the patient, at 10 min and 1 hr after the end of the attack, and after 
the attack had ended at the next of the predetermined times ("post"). Units of measurement are on the left-hand ordinate 
and measured variables are indicated in the upper right-hand corner of each frame. Mean ~ SEM for each variable 
is represented; no error bar is visible when the standard error fell within the dot representing the mean, Standard errors 
are sometimes small for "pre" and "post" times because the same values are sometimes represented more than once. 
at the peaks  o f  the attacks w e r e  stat ist ical ly  s igni f icant ly  h igher  than the " p r e "  base l ine .  
Somatostat in  concentrat ions ,  determined during attacks for t w o  o f  the patients (not sh o w n ) ,  were  
in the normal  range.  
Prolact in  concentrat ions  at the peak  o f  attack w e r e  s igni f icant ly  corre lated with  subject ive  
attack sever i ty  (r  = + 0 . 7 0 ,  p = 0 . 0 5 ) .  N o  sex  d i f ference  in mean  base l ine  24-hr  prolact in 
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was observed (M: 14.07 ng/ml; F: 14.30 ng/ml). All similar correlations for the other variables 
ranged between -0 .25  and +0.19; none approached statistical significance. When the level 
of the "p re"  baseline level was included (regression analysis), the multiple-R for prolactin 
remained significant (0.72); furthermore, the values for epinephrine (0.94) and cortisol (0.75) 
were also significant, and the value for heart rate (0.67) approached significance. While the 
significant multiple-R for epinephrine does not appear to have physiological importance, because 
of the lack of a physiologically meaningful change in epinephrine levels during the attacks, the 
results for cortisol, and possibly heart rate, suggest that increases are occurring in association 
with the more severe attacks, but that variations in baseline values sometimes tend to obscure them. 
The individual panic attack data (Table II) showed consistencies between subjects as well as 
individual differences. All attacks but two showed higher peak prolactin than baseline, and for 
all but one, peak prolactin was higher than after the attack was over. Growth hormone showed 
no changes except in one patient; in both of the attacks of this patient substantial increases (to 
8.91 ng/ml at the end of one attack, and 36.30 ng/ml at the peak of the other) occurred. Cortisol 
showed increases in seven attacks and decreases in two; norepinephrine showed increases in 
six attacks; MHPG showed mixed changes across subjects; and epinephrine showed no changes 
of physiological significance. All hormone changes except the growth hormone changes in one 
patient were small to moderate in magnitude. 
Six of the attacks were associated with a decrease in oral temperature (possibly due to 
hyperventilation); heart rate rose during five attacks but did not clearly rise in the others; and 
blood pressure showed primarily increases but also decreases in both systolic and diastolic 
pressure, with no consistent pattern between or within patients. Results from the Holter monitors 
indicated heart rate increases during some attacks, to a maximum of 150 beats per min during 
one, but no obvious increases in other attacks. By Holter monitoring, two patients who had 
attacks and two who did not had rare atrial premature beats and/or rare to frequent ventricular 
premature beats. Normal subjects had no dysrhythmias. 
Three of the four patients who had attacks had more than one (four, two and two). The data 
were inspected to determine if any consistencies of response pattern for the variables within 
each subject across attacks could be discerned. Although the numbers were small, a few patterns 
are suggested. Prolactin showed consistent increases in two of these subjects. One subject with 
two attacks had substantial rises in growth hormone during both attacks (above), while for the 
other subjects, growth hormone was consistently unchanged; this was the only patient who did 
not show prolactin increases. Norepinephrine showed increases during both attacks in both of 
the patients who had two attacks, but inconsistent changes during the four attacks in the other 
subject. As noted above, epinephrine did not show significant changes in any subject. The other 
six variables (cortisol, MHPG, heart rate, oral temperature and systolic and diastolic blood 
pressure) showed inconsistent variations within and between subjects. 
At the six predetermined times and during each panic attack, 100 mm line analog scales were 
completed for the seven symptom complexes. Inspection of the results indicated that, as expected, 
patients were higher than normal subjects, and increases from baseline values during attacks 
were greatest and most consistent for "panic",  " w o r r i e d . . . "  and "confused",  in that order. 
"Tense . . . " ,  " s a d . . . "  and " t i red" showed less consistent changes and "feeling good" 
was least. As noted above, the ratings of attack severity from 0 (none) to 10 (most ever) averaged 
6.22 for all nine attacks. 
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DISCUSSION 
This is the first study of hormonal changes during" spontaneous" panic attacks. Plasma growth 
hormone, cortisol and especially prolactin increases appeared to occur during at least some attacks, 
with definite individual differences in the patterns of endocrine response. Plasma epinephrine 
and the catechol metabolite MHPG did not show consistent increases during attacks, and there 
TABLE II. VALUES BEFORE, DURING AND AFTER ATTACKS 
No. Time 
Plasma Plasma Plasma Systolic Diastolic Heart 
Plasma growth Plasma norepi- epi- Plasma blood blood rate Body 
prolactin hormone cortisol nephrine nephrine M H P G  pressure pressure (beats/ temperature 








7 8.95 0.17 6.82 212 27 2.20 117 78 61 98.2 
9.84 0.18 1.68 264 18 3.01 124 80 64 97.8 
11.11 2.93 1.48 202 29 2.60 116 80 60 98.4 
8.75 0.96 2.42 198 13 2.60 - - 80 97.6 
9.04 0.33 2.58 274 14 4.51 109 75 60 97.2 
9 9.04 0.33 2.58 274 14 4.51 109 75 60 97.2 
15.91 0.20 16.32 162 14 2.50 104 70 60 97.7 
15.38 0.17 13.32 127 11 2.90 112 70 64 96.9 
12.77 0.17 12.36 133 20 2.30 110 74 60 97.5 
9.71 0.17 12.84 163 25 2.60 114 70 60 97.2 
8.98 1.33 15.26 - - - 112 72 66 97.3 
4 9.04 0.33 2.58 274 14 4.51 109 75 60 97.2 
10.22 0.18 9.56 140 18 2.40 120 80 60 97.0 
- 0.26 9.24 176 13 3.10 106 70 60 96.9 
11.18 0.24 13.12 136 18 2.50 110 76 68 97.2 
8.98 1.32 15.26 160 18 2.90 110 80 68 97.1 
. . . . . .  112 72 66 97.3 
9 8.98 1.32 15.26 160 18 2.90 112 72 66 97.3 
29.95 1.20 24.78 226 24 2.70 120 74 64 97.5 
12.66 0.45 18.22 196 20 2.90 120 80 60 97.4 
12.58 0.33 18.94 146 10 3.30 114 70 68 98.1 
8.17 0.33 22.04 320 22 3.20 110 60 69 97.7 
11.37 0.22 19.02 178 29 2.90 118 72 73 97.9 
5 8.78 1.73 19.58 185 24 2.44 108 69 55 97.8 
11.09 0.51 24.28 208 19 2.99 . . . .  
. . . . . .  110 72 64 97.9 
8.25 0.63 16.20 267 41 3.58 122 70 60 97.8 
10.30 0.56 19.26 218 33 2.08 100 64 56 97.8 
9.05 1.25 11.74 149 16 1.98 103 60 55 98.1 
5 8.78 1.73 19.58 185 24 2.44 108 69 55 97.8 
11.12 0.58 26.30 238 25 2.63 114 60 64 97.6 
13.37 0.64 24.26 235 34 2.88 94 64 64 - 
10.15 0.60 15.76 183 23 2.67 112 70 64 97.9 
9.05 1.25 11.74 149 16 1.98 103 60 55 98.1 
6 - 0.71 11.00 - - 1.94 90 60 76 97.7 
- 0.53 15.66 - - 4.68 110 80 96 96.4 
- 1.56 25.16 - - 2.11 92 66 56 97.0 
- 3.64 15.36 - - 2.65 86 60 64 97.0 
- 6.41 18.70 - - 1.91 114 97 64 97.6 
Table H continued on p. 328 
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TABLE I1 CONTINUED. VALUES BEFORE. DURING AND AFTER ATTACKS 
No. Time 
Plasma 
Plasma growth Plasma 
prolactin hormone cortisol 
Severity (ng/ml) (ng/rnl) (#g/dl) 
Plasma Plasma Systolic Diastolic Heart 
norepi- epi- Plasma blood blood rate Body 
nephrine nephrine MHPG pressure pressure (beats/ temperature 





10.38 3.59 6.90 222 
9.36 2.53 9.52 354 
8.65 8.91 6.48 319 
8.20 9.10 4.76 381 
7.90 21.80 3.16 290 
7.82 0.41 4.70 235 
11.00 0.42 23.90 213 
5.57 36.30 20.58 327 
6.47 21 .10  13.98 307 
5.29 11.10 11.84 - 
9.16 2.24 15.70 230 
51 - 133 74 87 98.6 
45 1.68 120 84 72 97.7 
45 2.09 120 84 64 98.6 
45 2.88 104 72 68 97.7 
37 2.64 130 84 64 97.7 
46 - 120 72 78 98.4 
48 - 112 72 78 99.2 
46 2.35 126 78 84 96.6 
52 2.28 122 70 72 97.5 
- - 112 70 76 98.0 
40 - 129 65 73 98.0 
Missing values were due to (a) time points being too close together to collect two specimens or make two measurements, 
(b) loss of specimen or (c) inability of assay to detect levels of substance in specimen (norepinephrine and epinephrine 
No. 4). Pre-baseline, attack peak, end of attack, 10 min post-attack, 1 hr post-attack and post-baseline values are listed 
for each variable for each attack. 
was actually a tendency for urinary excretion of  unconjugated epinephrine and norepinephrine 
to be lower in patients who did not have attacks than in normal subjects; plasma levels of  all 
substances measured at predetermined times were normal. Physiological measurements showed 
no changes during attacks, except for variable increases in heart rate and decreases in oral 
temperature (which might not reflect decreases in core temperature); all physiological  variables 
were normal at the predetermined times of  measurement. No abnormality of  circadian patterns 
was observed. 
Cardiac symptoms are usually associated with anxiety and panic attacks, and attacks are often 
associated with discernible increases in heart rate (Lader and Mathews,  1970; Taylor  et a l . ,  
1982, 1986; Freedman et al . ,  1985; Shear, 1986). However ,  of  a total of  49 attacks studied 
in ambulatory panic patients (including Taylor  et a l . ,  1982, 1986; Freedman et al . ,  1985), 20 
(41%) were not associated with identifiable increases, as determined by Holter monitoring. The 
present study suggests that heart rate increases may be even less common in supine subjects. 
Also,  heart rate may not be elevated in panic patients at times when attacks are not actually 
occurring (Freedman et al . ,  1985). Thus, the occasional lack of  heart rate change we observed 
is not necessarily an anomalous finding. Furthermore,  subjective reports of  increased heart rate 
might reflect as much an increased awareness of  heart action as an actual rate increase (Tyrer 
et al . ,  1980; Pyke and Greenberg,  1986), especially since there may be an association between 
heart rate increase and attack severity as suggested by our regression analysis. Finally,  similar 
to Shear (1986), but not Taylor  et al. (1986), we observed cardiac rhythm disturbances in some 
patients. 
Based on prior studies of  pharmacologically or situationally precipitated panic attacks (Appleby 
et al . ,  1981; Ko et al . ,  1983; Charney et al . ,  1984), increases in catecholamines and MHPG 
during attacks were expected, but they were not observed. Other research (Liebowitz et al . ,  
1985, 1986; Carr  et al . ,  1986) has indicated no differential change between patients and normal 
subjects in epinephrine or norepinephrine during lactate infusions. Decreases in urinary 
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epinephrine contrast with increases in a prior study (Nesse et al. ,  1985b); however, that study 
was in ambulatory patients and, similar to heart rate response, posture and activity may be an 
important difference. Effects of lactate on cortisol are minimal (Appleby et al., 1981; Liebowitz 
et al. ,  1985, 1986; Cart et al.,  1986) and caffeine stimulates cortisol release equally in patients 
and normal controls (Charney et al. ,  1985). Growth hormone has not shown any difference 
between patients and normals in response to lactate (Carr et al.,  1986). Thus, lack of consistent 
change in epinephrine and MHPG and variable increases in cortisol and growth hormone during 
"spontaneous" panic attacks (in supine otherwise-resting individuals) are not unexpected findings. 
Similar to several prior studies of panic patients (Appleby et al.,  1981; Grunhaus et al., 1983; 
Liebowitz et al. ,  1985, 1986; Carr et al.,  1986; Charney and Heninger, 1986; Roy-Byrne et 
al. ,  1986a), baseline prolactin levels in our study were normal. Although prior studies (Appleby 
et al.,  1981; Liebowitz et al. ,  1985, 1986; Charney and Heninger, 1986) found sex differences, 
with prolactin in women higher than in men, we found no sex difference. Lactate produced 
a rise in prolactin (Appleby et al.,  1981; Liebowitz et al.,  1985, 1986; Cart et al.,  1986). Male 
patients who had attacks may have had a more vigorous prolactin response to lactate than male 
patients who did not, although this was not reported as significant (Appleby et al., 1981; Liebowitz 
et al. ,  1985, 1986); female patients did not show this effect. Patients and normals had equal 
magnitude increases in prolactin after tryptophan administration (Charney and Heninger, 1986). 
Finally, patients showed a normal response to the cold pressor test (Graunhaus et al. ,  1983), 
but a reduced prolactin response to TRH, only in female patients (Roy-Byrne et al. ,  1986a). 
Thus, our study is in agreement with prior studies of baseline prolactin levels. The prolactin 
response to TRH is subsensitive, but prolactin rises during "spontaneous" panic, and it may 
increase somewhat during lactate-induced panic as well, at least in men. Prolactin increases 
thus might serve as a marker of the occurrence of a panic attack. 
The association of prolactin with CNS neurotransmission has been studied. Rises in prolactin 
suggest reduced dopaminergic and/or possibly cholinergic input during an attack, and/or an 
increase in serotonergic, opioid, GABAergic, and/or histaminergic influences (Checkley, 1980; 
Reichlin, 1985; Tuomisto and Mannisto, 1985); noradrenergic effects are mixed, and other 
neurotransmitters are also likely to be involved. The only neurotransmitter among those listed 
above which is associated with a rise in prolactin but with no rise in growth hormone, ACTH 
(and, therefore, cortisol), and somatostatin may be GABA (Tuomisto and Mannisto, 1985), 
although not all reviewers have indicated this exact pattern (Checkley, 1980; Elias et al.,  1982; 
Reichlin, 1985). Thus, the endocrine results of our study seem to be most consistent with a 
GABA effect, and GABA neurotransmission has been implicated in anxiety, due to the effects 
of benzodiazepines on the GABA receptor (Paul et al.,  1981). It is not clear which 
neurotransmitters are involved in the prolactin response to TRH; this response may be mediated 
at the pituitary level directly. 
McIntyre et al. (1986) reported lower plasma melatonin at midnight in 13 panic patients than 
in normal subjects; however, only one of their patients was drug-free. Three of our patients 
had panic attacks in the evening or night, when melatonin would be expected to be relatively 
high (Lewy, 1983). Melatonin concentrations were determined in two of our patients (Nos 2 
and 6). Concentrations in these patients were substantially lower than expected at the peaks of 
the three attacks studied (3.5, 4.6 and 1.7 pg/ml), which occurred while subjects were in the 
dark or modest room light. Thus, these very preliminary results support the earlier findings 
of a melatonin reduction in panic patients at night. 
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More attacks, including a range of severity, must be studied to determine if our results are 
consistent, including any between-patient variability and/or within-patient consistency of pattern 
of endocrine changes. Also, since some prior studies reported endocrine and physiological 
abnormalities in panic patients when attacks were not occurring and under different conditions 
from those of our study (i.e. ambulatory or resting for a shorter period of time), replication 
of our baseline results is necessary. Only when consistent patterns are identified will it be possible 
to make confident inferences about the neurotransmitters involved. In the meantime, these and 
prior results indicate that systemic increases in catecholamines, especially epinephrine, are 
minimal or non-existent in association with panic and therefore are not making any significant 
contribution to adrenergic symptom production during panic attacks and that the psychobiology 
of panic attacks in people with panic disorder is probably different from the psychobiology of 
stress in normal subjects. 
Note added in proof." Woods et al. (1987) recently reported some similar and some divergent 
physiologic and biochemical effects during situational panic attacks. 
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